Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 671

Sort by

Sort Order Select

Journal Articles

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

Anna Saorin, Anna Dehler, Bartimée Galvan, Fabio Daniel Steffen, Marine Ray, Dong Lu, Xin Yu, James Kim, Aneta Drakul, Samanta Kisele, Jin Wang, Jean-Pierre Bourquin, Beat Bornhauser

Blood blood.2025028938.

https://doi.org/10.1182/blood.2025028938

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of the STOPAGO study

Blood (2025) 145 (2): 244–247.

https://doi.org/10.1182/blood.2024025707

Published: 2025

Includes: Supplemental data

Journal Articles

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

Julia Costea, Kerstin K. Rauwolf, Pietro Zafferani, Tobias Rausch, Anna Mathioudaki, Judith Zaugg, Martin Schrappe, Cornelia Eckert, Gabriele Escherich, Jean-Pierre Bourquin, Beat Bornhauser, Andreas E. Kulozik, Jan O. Korbel

Blood (2024) 144 (Supplement 1): 314.

https://doi.org/10.1182/blood-2024-199619

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Blood (2024) 144 (Supplement 1): 968.

https://doi.org/10.1182/blood-2024-198419

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Mimi Chen, Wenbin Mo, Gennaro Clando, Yuanyuan Tian, Ciril Abraham, Qingrong Huang, Ying WANG, Morgan Chaunzwa, Yan Zhou, Andrew Ip, Andre Goy, Jaroslav Jelinek, Jozef Madzo, Jean-Pierre Issa, Yi Zhang

Blood (2024) 144 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2024-207438

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

Endothelial Protein C Receptor CD201 Enables Identification of Transplantable Mouse Hematopoietic Stem Cells in Inflammatory Conditions Unlike SCA1

Kavita Bisht, Svetlana Shatunova, Valerie Barbier, Ingrid G Winkler, Jean-Pierre Levesque

Blood (2024) 144 (Supplement 1): 1286.

https://doi.org/10.1182/blood-2024-199946

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

Mohamed Ali, Emily Limerick, Matthew Hsieh, Kalpana Upadhyaya, Xin Xu, Oswald Phang, Jean Pierre Kambala Mukendi, Katherine R. Calvo, Maria Lopez-Ocasio, Pradeep Dagur, Courtney Fitzhugh

Blood (2024) 144 (Supplement 1): 2167.

https://doi.org/10.1182/blood-2024-207487

Published: 2024

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Kavita Bisht, Yoon-Kyo An, Svetlana Shatunova, Ran Wang, Valerie Barbier, Rabina Giri, Anna Amiss, Yifu Tang, Kylie Alexander, Susan Millard, Ingrid G Winkler, Allison Pettit, Jakob Begun, Jean-Pierre Levesque

Blood (2024) 144 (Supplement 1): 166.

https://doi.org/10.1182/blood-2024-193349

Published: 2024

Journal Articles

Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Blood (2024) 144 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2024-208350

Published: 2024

Journal Articles

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Ying WANG, Qingrong Huang, Ruqayyah sanders-Braggs, Yan Zhou, Robert Hooper, Yuanyuan Tian, Tatiana Kent, Richard Pomerantz, Gennaro Clando, Jean-Pierre Issa, Jonathan Soboloff, Yi Zhang

Blood (2024) 144 (Supplement 1): 4769.

https://doi.org/10.1182/blood-2024-212207

Published: 2024

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

Ciril Abraham, Wenbin Mo, Tien Bui, Mimi Chen, Yuanyuan Tian, Gennaro Clando, Morgan Chaunzwa, Ying WANG, Jozef Madzo, Jean-Pierre Issa, Yi Zhang

Blood (2024) 144 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2024-211530

Published: 2024

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Ying Wang, Shan He, Gennaro Calendo, Tien Bui, Yuanyuan Tian, Che Young Lee, Yan Zhou, Xin Zhao, Ciril Abraham, Wenbin Mo, Mimi Chen, Ruqayyah Sanders-Braggs, Jozef Madzo, Jean-Pierre Issa, Elizabeth O. Hexner, David L. Wiest, Ran Reshef, Hai-Hui Xue, Yi Zhang

Blood (2024) 143 (2): 166–177.

https://doi.org/10.1182/blood.2023021126

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

Long-term follow-up of the STOPAGO study

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Endothelial Protein C Receptor CD201 Enables Identification of Transplantable Mouse Hematopoietic Stem Cells in Inflammatory Conditions Unlike SCA1

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only